Xeris Biopharma Holdings Statistics
Total Valuation
XERS has a market cap or net worth of $844.02 million. The enterprise value is $1.05 billion.
Important Dates
The next estimated earnings date is Thursday, August 7, 2025, before market open.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
XERS has 160.16 million shares outstanding. The number of shares has increased by 8.11% in one year.
| Current Share Class | 160.16M |
| Shares Outstanding | 160.16M |
| Shares Change (YoY) | +8.11% |
| Shares Change (QoQ) | +2.25% |
| Owned by Insiders (%) | 4.59% |
| Owned by Institutions (%) | 54.59% |
| Float | 152.80M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.55 |
| Forward PS | 2.96 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.74 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.72
| Current Ratio | 1.72 |
| Quick Ratio | 1.10 |
| Debt / Equity | n/a |
| Debt / EBITDA | 98.08 |
| Debt / FCF | n/a |
| Interest Coverage | -0.53 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -3.14% |
| Return on Invested Capital (ROIC) | -4.15% |
| Return on Capital Employed (ROCE) | -7.44% |
| Revenue Per Employee | $564,850 |
| Profits Per Employee | -$114,406 |
| Employee Count | 394 |
| Asset Turnover | 0.68 |
| Inventory Turnover | 0.85 |
Taxes
| Income Tax | -2.58M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +143.98% in the last 52 weeks. The beta is 0.85, so XERS's price volatility has been lower than the market average.
| Beta (5Y) | 0.85 |
| 52-Week Price Change | +143.98% |
| 50-Day Moving Average | 4.72 |
| 200-Day Moving Average | 3.93 |
| Relative Strength Index (RSI) | 68.45 |
| Average Volume (20 Days) | 2,116,159 |
Short Selling Information
The latest short interest is 17.94 million, so 11.20% of the outstanding shares have been sold short.
| Short Interest | 17.94M |
| Short Previous Month | 17.60M |
| Short % of Shares Out | 11.20% |
| Short % of Float | 11.74% |
| Short Ratio (days to cover) | 8.71 |
Income Statement
In the last 12 months, XERS had revenue of $222.55 million and -$45.08 million in losses. Loss per share was -$0.30.
| Revenue | 222.55M |
| Gross Profit | 182.96M |
| Operating Income | -16.39M |
| Pretax Income | -59.08M |
| Net Income | -45.08M |
| EBITDA | -4.33M |
| EBIT | -16.39M |
| Loss Per Share | -$0.30 |
Full Income StatementBalance Sheet
The company has $58.44 million in cash and $268.75 million in debt, giving a net cash position of -$210.31 million or -$1.31 per share.
| Cash & Cash Equivalents | 58.44M |
| Total Debt | 268.75M |
| Net Cash | -210.31M |
| Net Cash Per Share | -$1.31 |
| Equity (Book Value) | -35.13M |
| Book Value Per Share | -0.23 |
| Working Capital | 68.42M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$26.71 million and capital expenditures -$717,000, giving a free cash flow of -$27.43 million.
| Operating Cash Flow | -26.71M |
| Capital Expenditures | -717,000 |
| Free Cash Flow | -27.43M |
| FCF Per Share | -$0.17 |
Full Cash Flow StatementMargins
Gross margin is 82.21%, with operating and profit margins of -7.37% and -20.25%.
| Gross Margin | 82.21% |
| Operating Margin | -7.37% |
| Pretax Margin | -21.41% |
| Profit Margin | -20.25% |
| EBITDA Margin | -1.95% |
| EBIT Margin | -7.37% |
| FCF Margin | n/a |
Dividends & Yields
XERS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.11% |
| Shareholder Yield | -8.11% |
| Earnings Yield | -5.34% |
| FCF Yield | -3.25% |
Analyst Forecast
The average price target for XERS is $6.25, which is 18.60% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.25 |
| Price Target Difference | 18.60% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 19.64% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
XERS has an Altman Z-Score of -1.48 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.48 |
| Piotroski F-Score | 3 |
